{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-056018","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.637818+00:00","generated_at":"2026-06-15T21:21:53.360923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Protagonist Q1 net loss $33.7M; positive Phase 2b data for JNJ-2113; cash runway to 2025","bullets":["Net loss $33.7M ($0.67/share) vs $20.9M loss in Q1 2022; license revenue zero (prior year $25.7M milestone).","Positive Phase 2b FRONTIER 1 topline data for JNJ-2113 in psoriasis: PASI-75 met across all dose groups vs placebo.","Phase 2 REVIVE rusfertide data: 69.2% responders vs 18.5% placebo (p=0.0003); phlebotomy free 92.3% vs placebo.","Closed public offering of 5.75M shares at $20 each; net proceeds $108.1M; cash runway now through end of 2025.","Cash and marketable securities $230.8M; R&D expenses $27.4M (down from $36.3M); G&A $8.6M (down from $10.5M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-056018","json":"https://secwatch.observer/filing/0001104659-23-056018.json","markdown":"https://secwatch.observer/filing/0001104659-23-056018.md","text":"https://secwatch.observer/filing/0001104659-23-056018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923056018/0001104659-23-056018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923056018/tm2314649d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:21:53.360923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7cfe4ea467a4e6ef5f2913d2ab8f85d5694c3612","claim":"Protagonist Therapeutics, Inc reported the first quarter ended March 31, 2023 results: revenue zero.","evidence_excerpt":"License and collaboration revenue for the first quarter 2023 was zero, as compared to $25.7 million for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923056018/0001104659-23-056018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"zero"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}